Quick Answer
Avalo Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $59.0 thousand for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -86.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Avalo Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 99.8%.
- Historical annual values: Fiscal year 2025: $59.0 thousand | Fiscal year 2024: $441.0 thousand | Fiscal year 2023: $1.92 million | Fiscal year 2022: $18.05 million | Fiscal year 2021: $5.40 million | Fiscal year 2020: $6.70 million | Fiscal year 2019: $6.75 million | Fiscal year 2018: $7.03 million | Fiscal year 2017: $27.81 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: